Henry v. Mutual of Omaha Insurance

503 F.3d 425, 2007 U.S. App. LEXIS 23509, 2007 WL 2897966
CourtCourt of Appeals for the Fifth Circuit
DecidedOctober 5, 2007
Docket06-41571
StatusPublished
Cited by6 cases

This text of 503 F.3d 425 (Henry v. Mutual of Omaha Insurance) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Henry v. Mutual of Omaha Insurance, 503 F.3d 425, 2007 U.S. App. LEXIS 23509, 2007 WL 2897966 (5th Cir. 2007).

Opinion

PER CURIAM:

On behalf of their deceased son, the Plaintiffs-Appellants Marion Jack Henry and Janet K. Henry (the “Henrys”) filed suit in Texas state court against Defendant-Appellee Mutual of Omaha Insurance Company (“MOIC”), the issuer of their son’s health insurance coverage, alleging that MOIC’s denial of coverage for intravenous immunoglobulin (“IVIG”) replacement therapy caused their son, Bradley David Henry (“Brad”), to commit suicide. MOIC removed the case to district court, which granted MOIC’s motion for summary judgment. We affirm.

I. FACTS AND PROCEEDINGS

A. Facts

Brad had purchased a health insurance policy from MOIC which covered the expense of services and supplies for the treatment of medically necessary injuries and sickness. Brad’s insurance policy defined a medically necessary service or supply as one that: “(a) is appropriate and consistent with the diagnosis in accord with accepted standards of community practice; (b) is not experimental or investigative; (c) could not have been omitted without adversely affecting the insured person’s condition or quality of medical care; and (d) is delivered at the lowest and most appropriate level of care and not primarily for the sake of convenience.” MOIC rejected the medical necessity of Brad’s prescribed IVIG treatment. Brad subsequently committed suicide.

The dispute between Brad and MOIC began in 2002, after Dr. Michael Bullen diagnosed Brad with hypogammaglobuline-mia immunological deficiency and recommended Brad undergo monthly IVIG infusions for one year. A second opinion from Dr. Glenn Bugay confirmed Dr. Bullen’s diagnosis and concurred in the prescribed IVIG treatment. Dr. Bullen administered Brad’s first IVIG treatment on December 10, 2002. On that same date, Dr. Bullen’s office phoned MOIC to verify that Brad’s policy would cover IVIG treatment, which was expensive (from $10,000 to $16,000 per monthly session). MOIC’s oral response was non-committal.

Dr. Bullen followed up his phone call with a formal letter to MOIC on December 26, 2002, in which he requested a “predetermination” that Brad’s policy would cover one year of monthly IVIG infusions. Dr. Bullen’s predetermination request included his professional opinion (along with fifteen pages of notes and other supporting documents) that the prescribed treatment was medically necessary.

A physician employed by MOIC reviewed the claim and determined that Brad might not need or benefit from the prescribed IVIG treatment. MOIC also consulted an independent immunologist for a second opinion. That doctor similarly recommended that MOIC deny Brad’s claim for IVIG treatment. Armed with two proffered opinions that IVIG therapy was not medically necessary, MOIC notified Dr. Bullen that Brad’s policy would not cover his IVIG treatments.

After this initial rejection, Dr. Bugay, at Dr. Bullen’s urging, wrote to MOIC, reiterating his and Dr. Bullen’s agreement that IVIG treatment was medically necessary for Brad. MOIC forwarded Brad’s file to a second in-house physician — the third MOIC-affiliated doctor to review it — • *427 who concluded that there was no basis for changing the initial recommendations. By a letter dated March 8, 2003, MOIC notified Dr. Bullen and Brad that it stood by its original determination of no coverage. MOIC also informed Dr. Bullen and Brad of their right to request review of its decision by an independent organization and provided the forms to be used in requesting such a review. Dr. Bullen and Brad never requested an independent review.

Despite MOIC’s two official rejections of the claim, Dr. Bullen continued to administer monthly IVIG treatments to Brad and to request reimbursement from MOIC; and MOIC paid Dr. Bullen’s invoices for' Brad’s December, January, February, and March treatments. In a letter dated April 2, 2003, however, MOIC notified Dr. Bul-len and Brad that the benefits for previous treatments had been paid in error “[d]ue to the confusion of our previous handling,” but that charges for IVIG treatments after April 1, 2003 “will be handled per policy provisions regarding medical necessity, based on the information currently in file,” viz., denied unless new information surfaced regarding the medical necessity of Brad’s claim. MOIC again reminded Dr. Bullen and Brad of their right to seek a review by an independent organization and invited them to submit any additional relevant documentation.

Brad then consulted Dr. Howard Rosen-blatt of the Allergy and Immunology Clinic at Houston’s Texas Children Hospital. Dr. Rosenblatt performed a thorough history and physical examination and ordered numerous laboratory tests. Unlike Drs. Bugay and Bullen, Dr. Rosenblatt did not unequivocally conclude that the IVIG treatment was medically necessary, but did report that “it would be expected that [Brad] would derive clinical benefit from IVIG replacement therapy.” Dr. Rosen-blatt also recommended that Brad’s dosing schedule be modified to increase the amount of monthly dosage of IVIG or to increase the frequency with which the current dosage was administered from every month to every two to three weeks. Thus Dr. Rosenblatt did recommend IVIG therapy for Brad, becoming the third doctor to do so.

On May 1, 2003, Brad received his fifth IVIG treatment. One week later, Brad forwarded Dr. Rosenblatt’s report to MOIC with an accompanying note stating that he intended to continue his IVIG therapy “as this is my only alternative for a reasonably functional life, to maintain a job and have some hope of not being chronically ill.”' MOIC sent Dr. Rosenblatt’s report to yet another independent physician for a review of the claim. Before this review was completed, Brad contacted MOIC for an update on the status of his claim. MOIC informed him that an independent physician- — -the fourth doctor assigned to the case by MOIC — was in the process of reviewing the new information from Dr. Rosenblatt and that this latest review would take a couple of weeks to complete. Brad threatened legal action if MOIC continued to reject his claim, but four days later (and five days before his wedding was to take place) Brad committed suicide.

On June 2, 2003, MOIC’s second independent physician reviewer concurred in the recommendation of MOIC’s three previously contracted doctors. After learning that Brad had committed suicide, MOIC paid for Brad’s fifth and final IVIG treatment.

B. Prior Proceedings

The Henrys filed suit in Texas state court against MOIC and an insurance agent, alleging breach of contract and breach of the duty of good faith and fair dealing under the common law, Article 21.21 of the Texas Insurance Code, 1 and *428 the Texas Deceptive Trade Practices Act (“DTPA”). 2 These claims were brought pursuant to the Texas Survival Statute, which allows an executor to pursue causes of action on behalf of a decedent’s estate. 3 Brad’s estate sought damages for his physical pain and mental anguish before his death, funeral and burial expenses, and punitive damages.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
503 F.3d 425, 2007 U.S. App. LEXIS 23509, 2007 WL 2897966, Counsel Stack Legal Research, https://law.counselstack.com/opinion/henry-v-mutual-of-omaha-insurance-ca5-2007.